FDA Approves CARVYKTI (ciltacabtagene autoleucel; cilta-cel) for Relapsed or Refractory Multiple Myeloma Patients Who Have Received at Least One Prior Line of Therapy (https://www.myeloma.org/news-events/multiple-myeloma-news/fda-approve-carvykti-rrmm)